Platform Technology and Science, GlaxoSmithKline , 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States.
Anal Chem. 2018 Feb 20;90(4):2970-2975. doi: 10.1021/acs.analchem.8b00180. Epub 2018 Feb 8.
We demonstrate a high-throughput chemoprinting platform that confirms the consistency in the higher-order structure of protein biologics and is sensitive enough to detect single-point mutations. This method addresses the quality and consistency of the tertiary and quaternary structure of biologic drug products, which is arguably the most important, yet rarely examined, parameter. The method described uses specific small-molecule ligands as molecular probes to assess protein structure. Each library of probe molecules provides a "fingerprint" when taken holistically. After proof-of-concept experiments involving enzymes and antibodies, we were able to detect minor conformational perturbations between four 48 kDa protein mutants that only differ by one amino acid residue.
我们展示了一种高通量化学打印平台,该平台证实了蛋白质生物制剂的高级结构的一致性,并且足够灵敏,可以检测单点突变。该方法解决了生物药物产品的三级和四级结构的质量和一致性问题,这可以说是最重要的,但很少被检查的参数。所描述的方法使用特定的小分子配体作为分子探针来评估蛋白质结构。每个探针分子库整体上提供一个“指纹”。在涉及酶和抗体的概念验证实验之后,我们能够检测到四个 48 kDa 蛋白质突变体之间仅相差一个氨基酸残基的微小构象变化。